Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Interpreting clinical trial data for daily clinical practice: How to work with what we have available in second-line

Gero Kramer

16 Interpreting clinical trial data for daily clinical practice: How to work with what we have available in second-line

Most important for improving outcomes of patients with metastatic castration resistant prostate cancer (mCRPC) are prognostic indicators that stratify the patients. Prognostic markers like nadir prostate-specific antigen, splice variants such as AR-V7 or number of bone metastases may allow to subgroup the patients and to optimize treatment strategies outlines Professor Gero Kramer, AKH Medical University, Vienna.